Paweł Knapp1, Lubomir Bodnar2, Agnieszka Błachnio-Zabielska3, Magdalena Świderska4, Adrian Chabowski5. 1. Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, 24a Sklodowskiej-Curie Str., 15-276 Bialystok, Poland. Electronic address: knapp@umb.edu.pl. 2. Department of Clinical Oncology, Military Institute of Medicine in Warsaw, 128 Szaserow Str., 04-141 Warsaw, Poland. Electronic address: lbodnar@wim.mil.pl. 3. Department of Hygiene, Epidemiology and Metabolic Disorders, Medical University of Bialystok, 2c Mickiewicza Str., 15-222 Bialystok, Poland; Department of Physiology, Medical University of Bialystok, 2c Mickiewicza Str., 15-222 Bialystok, Poland. Electronic address: blacha@amb.edu.pl. 4. Department of Physiology, Medical University of Bialystok, 2c Mickiewicza Str., 15-222 Bialystok, Poland. Electronic address: magdalena.swiderska@umb.edu.pl. 5. Department of Physiology, Medical University of Bialystok, 2c Mickiewicza Str., 15-222 Bialystok, Poland. Electronic address: adrian@umb.edu.pl.
Abstract
PURPOSE: The role of lipids in carcinogenesis through induction of abnormal cell lines in the human body is currently undisputable. Based on the literature, bioactive sphingolipids play an essential role in the development and progression of cancer and are involved in the metastatic process. The aim of this study was to determine the concentration of selected sphingolipids in patients with advanced ovarian cancer (AOC, FIGO III/IV, high grade ovarian cancer). METHODS: Seventy-four patients with ovarian cancer were enrolled. Plasma concentrations of C16-Cer, C18:1-Cer and C18-Cer were assessed by LC/MS/MS. The content of tissue sphingolipids was measured using a UHPLC/MS/MS. RESULTS: Plasma concentration of 3 ceramides: C16-Cer, C18:1-Cer and C18-Cer was significantly elevated in women with advanced ovarian cancer compared to control group (P=0.031; 0.022; 0.020; respectively). There were increases in concentration of 5 ceramides: C16-Cer, C18:1-Cer, C18-Cer, C24:1-Cer, C24-Cer (P=0.025; 0.049; 0.032; 0.005; 0.013, respectively) and S1P (P=0.004) in ovarian tissue of women with advanced ovarian cancer compared to healthy individuals. Importantly, significantly higher risk of ovarian cancer when the plasma concentration of C16-Cer>311.88ng/100μl (AUC: 0.76, P=0.0261); C18:1-Cer>4.75ng/100μl (AUC: 0.77, P=0.0160) and C18-Cer>100.76ng/100μl (AUC:0.77, P=0.0136) was noticed. CONCLUSIONS: Bioactive sphingolipids play an essential role in the development and progression of cancer and they also take part in the process of metastasizing. This study suggests that some sphingolipids can be used as potential biomarkers of advanced ovarian cancer and that they can play an important role in the pathogenesis of this disease.
PURPOSE: The role of lipids in carcinogenesis through induction of abnormal cell lines in the human body is currently undisputable. Based on the literature, bioactive sphingolipids play an essential role in the development and progression of cancer and are involved in the metastatic process. The aim of this study was to determine the concentration of selected sphingolipids in patients with advanced ovarian cancer (AOC, FIGO III/IV, high grade ovarian cancer). METHODS: Seventy-four patients with ovarian cancer were enrolled. Plasma concentrations of C16-Cer, C18:1-Cer and C18-Cer were assessed by LC/MS/MS. The content of tissue sphingolipids was measured using a UHPLC/MS/MS. RESULTS: Plasma concentration of 3 ceramides: C16-Cer, C18:1-Cer and C18-Cer was significantly elevated in women with advanced ovarian cancer compared to control group (P=0.031; 0.022; 0.020; respectively). There were increases in concentration of 5 ceramides: C16-Cer, C18:1-Cer, C18-Cer, C24:1-Cer, C24-Cer (P=0.025; 0.049; 0.032; 0.005; 0.013, respectively) and S1P (P=0.004) in ovarian tissue of women with advanced ovarian cancer compared to healthy individuals. Importantly, significantly higher risk of ovarian cancer when the plasma concentration of C16-Cer>311.88ng/100μl (AUC: 0.76, P=0.0261); C18:1-Cer>4.75ng/100μl (AUC: 0.77, P=0.0160) and C18-Cer>100.76ng/100μl (AUC:0.77, P=0.0136) was noticed. CONCLUSIONS: Bioactive sphingolipids play an essential role in the development and progression of cancer and they also take part in the process of metastasizing. This study suggests that some sphingolipids can be used as potential biomarkers of advanced ovarian cancer and that they can play an important role in the pathogenesis of this disease.
Authors: Adam R Markowski; Agnieszka U Błachnio-Zabielska; Katarzyna Guzińska-Ustymowicz; Agnieszka Markowska; Karolina Pogodzińska; Kamila Roszczyc; Justyna Zińczuk; Piotr Zabielski Journal: Biomolecules Date: 2020-04-19
Authors: Paweł Knapp; Karolina Chomicz; Magdalena Świderska; Adrian Chabowski; Robert Jach Journal: Biomed Res Int Date: 2019-05-02 Impact factor: 3.411
Authors: Kamilah Castro; Achilles Ntranos; Mario Amatruda; Maria Petracca; Peter Kosa; Emily Y Chen; Johannes Morstein; Dirk Trauner; Corey T Watson; Michael A Kiebish; Bibiana Bielekova; Matilde Inglese; Ilana Katz Sand; Patrizia Casaccia Journal: EBioMedicine Date: 2019-04-10 Impact factor: 8.143
Authors: Maura E Walker; Vanessa Xanthakis; Linda R Peterson; Meredith S Duncan; Joowon Lee; Jiantao Ma; Sherman Bigornia; Lynn L Moore; Paula A Quatromoni; Ramachandran S Vasan; Paul F Jacques Journal: J Nutr Date: 2020-11-19 Impact factor: 4.798
Authors: Riikka Johanna Niemi; Elena Ioana Braicu; Hagen Kulbe; Kaisa Maria Koistinen; Jalid Sehouli; Ulla Puistola; Johanna Unelma Mäenpää; Mika Hilvo Journal: Br J Cancer Date: 2018-10-08 Impact factor: 7.640